EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids

Dominik Wenisch, Slavica Ždravac, Michael A Jakupec, Franz Jirsa, Bernhard K Keppler

Cancer Chemotherapy and Pharmacology · 22.05.2026 · 96 (1)

DOI: 10.1007/s00280-026-04902-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 22.05.2026. Verfasst von Dominik Wenisch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Spheroids, Cellular, Antineoplastic Combined Chemotherapy Protocols, Organometallic Compounds, Stomach Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BOLD-100, a ruthenium(III) prodrug also known as KP1339, is currently under clinical investigation for its suitability as a co-therapeutic anticancer drug. Unlike platinum-based chemotherapeutics, it has unique non-DNA targets, mainly GRP78, an enzyme responsible for signaling related to protein folding in the ER. Inhibition of this key mediator of the “unfolded protein response” may lead to cell death eventually. The purpose of this study was to assess in vitro the impact of BOLD-100 combinations with oxaliplatin, 5-FU, cisplatin or SN38 in multicellular tumor spheroids (MCTSs) compared to single-drug treatments. Gastric (MKN45, NCI-N87) and colorectal cancer (HCT116, HT29) cell lines were chosen, corresponding to the clinical trial in which patients with tumors of these origins are being treated. Biological effects investigated in this study include cytotoxic activity, synergism/antagonism based on Chou and Talalay’s algorithm, formation of reactive oxygen species (ROS) and induction of apoptosis and necrosis. Cytotoxicity tests showed vastly different chemosensitivities in MCTSs of the same tumor origin. In both tumor entities, partially synergistic effects were revealed when BOLD-100 was combined with the drugs mentioned above. The DCFH-DA assay suggested consistent increases of ROS levels after treatment with oxaliplatin and, with restrictions, its combination with BOLD-100. Apoptosis and necrosis were induced in the spheroid models by single-drug and combined treatment, with no hints at antagonism in the combination settings. In conclusion, these findings emphasize the potential of BOLD-100 for combination therapy of gastric and colorectal cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spheroids, CellularAntineoplastic Combined Chemotherapy ProtocolsOrganometallic CompoundsStomach NeoplasmsGastrointestinal NeoplasmsColorectal NeoplasmsHumansEndoplasmic Reticulum Chaperone BiPApoptosisOxaliplatinFluorouracilCisplatinReactive Oxygen SpeciesDrug SynergismCell Line, TumorIrinotecanAntineoplastic AgentsProdrugsHCT116 CellsHT29 CellsCamptothecin

Stichwörter der Autor:innen

Colon cancerCombination therapyGastric cancerIn vitro studiesMulticellular tumor spheroidsRuthenium drug

Substanzen

HSPA5 protein, humanOrganometallic CompoundsKP 1339Endoplasmic Reticulum Chaperone BiPOxaliplatinFluorouracilCisplatinReactive Oxygen SpeciesIrinotecanAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria.
  • Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria. michael.jakupec@univie.ac.at.
  • Research Cluster "Translational Cancer Therapy Research", University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria. michael.jakupec@univie.ac.at.
  • Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Josef-Holaubek-Platz 2, 1090, Vienna, Austria.
  • Research Cluster "Translational Cancer Therapy Research", University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria.

Förderung

  • University of Vienna

Zitieren

APA

Wenisch, D., Ždravac, S., Jakupec, M. A., Jirsa, F., & Keppler, B. K. (2026). Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04902-z

Vancouver

Wenisch D, Ždravac S, Jakupec MA, Jirsa F, Keppler BK. Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04902-z

BibTeX
@article{Wenisch2026,
  author = {Wenisch, Dominik and Ždravac, Slavica and Jakupec, Michael A and Jirsa, Franz and Keppler, Bernhard K},
  title = {Combinational studies of BOLD-100/KP1339 with established chemotherapeutics in gastrointestinal multicellular tumor spheroids},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04902-z}
}
Kostenlos starten →